California Judge Sides with Stem Cell Clinic Against the FDA
The Honorable Jesus Bernal (federal judge in Riverside), has issued his judgement in the United States of America Versus The California Stem Cell Treatment Center. Judge Bernal’s ruling has declared that the stem cells from your own fat are not a drug and the FDA was functioning outside its jurisdiction. Judge Bernal accepted that The […]
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
SUNNYVALE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP® Cell Therapy Heart Failure Trial (clinicaltrials.gov Identifier: […]
Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio
BOSTON and LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced seven presentations from across its neurometabolic portfolio will be featured at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place from August 30 to September 2, 2022, in Freiburg, […]
Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin
MARIETTA, Ga., Aug. 26, 2022 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today recognized Board Member, Cato T. Laurencin, M.D., Ph.D. for his leadership and contributions to advance the field of regenerative engineering. The Cato T. Laurencin Regenerative Engineering Founders’ Award has been established by […]
Combining Synthetic and Stem Cell Biology
Mark Kotter discusses how software-inspired approach to synthetic biology facilitates the targeting and reprogramming of entire sets of stem cells into other human cell types. By combining synthetic and stem cell biology, Mark and his team at bit.bio are providing stable supplies of human cell types for research and drug discovery. Video Transcript: (soft music) […]
Prominent ophthalmologist will guide Turn Bio’s search for therapies to cure eye diseases
MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire/ — Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic products as an advisor to the company. A board-certified ophthalmologist and fellowship-trained specialist in oculoplastic and orbital surgery, […]
ExoCoBio’s First Global Regenerative Aesthetic Exosome Summit
SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ — ExoCoBio will hold the world first “Regenerative Aesthetic Exosome Summit 2022” (hereinafter the “Summit”) under the topic of exosomes at the Marriott Hotel Dongdaemun on September 17~18. This Summit, co-hosted with BENEV company of the US and LG Chem of Korea, will be the world’s largest event […]
Harnessing Stem Cells to Treat Disease
Thanks to advances in techniques for culturing and genetically modifying patient cells, scientists developed myriad stem cell-based treatments for human diseases. Therapeutic success rates for stem cell-based treatments depend on whether scientists can provide the proper structural and molecular cues to form the cell types lacking in patients. In addition, to support successful engraftment, researchers […]
Immunis Announces FDA Clearance and Clinical Site for Phase 1/2a Clinical Trial Investigating Immune-Mediated Muscle Atrophy
IRVINE, Calif., Aug. 9, 2022 /PRNewswire/ — Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, today announced that the U.S. Food and Drug Administration has approved it’s Investigational New Drug application for a Phase 1/2a clinical trial investigating IMM01-STEM in participants with muscle atrophy: www.clinicaltrials.gov/ct2/show/NCT05211986 The open label […]
Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio
MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ — Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research. Sebastiano led development of the unique mRNA-based ERA™ (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored […]